Explore
Validate
Learn
Western blot
Immunocytochemistry
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-47004 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Activin A Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Reconstitute at 0.2 mg/mL in sterile PBS. Endoxin level is
- Reactivity
- Human, Mouse, Rat
- Host
- Goat
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 0.2 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references Profiling Activins and Follistatin in Colorectal Cancer According to Clinical Stage, Tumour Sidedness and Smad4 Status.
Refaat B, Zekri J, Aslam A, Ahmad J, Baghdadi MA, Meliti A, Idris S, Sultan S, Alardati H, Saimeh HA, Alsaegh A, Alhadrami M, Hamid T, Naeem ME, Elsamany SA
Pathology oncology research : POR 2021;27:1610032
Pathology oncology research : POR 2021;27:1610032
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry analysis of Activin A in immersion fixed SK‚BR‚3 human breast cancer cell line (left panel, positive stain) and HeLa human cervical epithelial carcinoma cell line (right panel, negative stain). Samples were incubated in Activin A polyclonal antibody (Product # PA5-47004) using a dilution of 5 µg/mL for 3 hours at room temperature followed by NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red) and counterstained with DAPI (blue). Specific staining was localized to endoplasmic reticuli.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of Activin A in immersion fixed paraffin-embedded sections of human breast cancer tissue. Samples were incubated in Activin A polyclonal antibody (Product # PA5-47004) using a dilution of 5 µg/mL overnight at 4 °C. Tissue was stained (red) and counterstained with hematoxylin (blue).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Neutralization of Activin A in K562 human chronic myelogenous leukemia cell line. Samples were incubated in Activin A polyclonal antibody (Product # PA5-47004). Recombinant Human/Mouse/Rat Activin A increases hemoglobin expression in the K562 human chronic myelogenous leukemia cell line in a dose-dependent manner (orange line), as measured by the psuedoperoxidase assay. Hemoglobin Expression elicited by Recombinant Human/Mouse/Rat Activin A (7.5 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human/Mouse/Rat Activin A βA subunit Antigen Affinity-purified Polyclonal Antibody. The ND50 is typically 2‚6 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- FIGURE 3 Localisation of activin betaA- and betaB-subunits alongside follistatin proteins by immunohistochemistry (IHC) in the FFPE ( n = 90 patients) and fresh ( n = 40 patients) cohorts of malignant colonic tissues according to clinical stages and tumour sidedness (Scale bar = 15 mum). Additionally, the relative protein expression of the targeted molecules in the malignant and normal colonic tissues according to cancer stage and tissue sidedness is shown as boxplots (a = p < 0.05 compared with right-sided normal tissue from early cancer; b = p < 0.05 compared with early stage right-sided colon cancer; c = p < 0.05 compared with left-sided normal tissue from early cancer; d = p < 0.05 compared with early stage left-sided colon cancer; e = p < 0.05 compared with right-sided normal tissue from advanced cancer; f = p < 0.05 compared with advanced stage right-sided colon cancer and g = p < 0.05 compared with left-sided normal tissue from advanced cancer).
